EUVIMEDEUVIMED entdecken
Crossref

Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations

Ciara Conduit iD, Jeremy Lewin iD, Andrew Weickhardt iD, James Lynam iD, Shirley Wong, Peter Grimison iD, Shomik Sengupta iD, Ganes Pranavan, Francis Parnis, Patricia Bastick, David Campbell, Aaron R Hansen iD und 8 weitere

JCO Oncology Practice · 2023-11 · 19 (11) · 973-980

DOI: 10.1200/op.23.00191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2023-11. Verfasst von Ciara Conduit und 19 weiteren Autor:innen. Beteiligte Einrichtung: Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Testicular Neoplasms, Seminoma, Prostatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE International guidelines advocate for active surveillance as the preferred treatment strategy for patients with stage 1 testicular cancer after orchidectomy although a personalized discussion is required. MATERIALS AND METHODS We conducted an analysis of individuals registered in iTestis, Australia's testicular cancer registry, to describe the patterns of relapse and outcomes of patients treated in Australia where the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations are widely adopted. RESULTS A total of 650 individuals diagnosed between 2000 and 2020 were included, 63% (411 of 650) seminoma and 37% (239 of 650) nonseminoma. The median age was 34 years (range 14-74). 26% (106 of 411) with seminoma and 15% (36 of 239) nonseminoma received adjuvant chemotherapy. After a median follow-up of 43 months (range 0-267) postorchidectomy, relapse occurred in 10% (43 of 411) of seminoma and 18% (43 of 239) of nonseminoma. The two-year relapse-free survival was 92% (95% CI, 89 to 95) and 82% (95% CI, 78 to 87) in seminoma and nonseminoma, respectively. All relapses (86 of 86) were detected at a routine surveillance visit; 98% (85 of 86) were asymptomatic and detected solely through imaging (62 of 86, 72%), tumor markers (6 of 86, 7%), or a combination (17 of 86, 20%). The most common relapse site was isolated retroperitoneal lymphadenopathy (53 of 86, 62%). No nonpulmonary visceral metastases occurred. At relapse, 98% (84 of 86) had International Germ Cell Cancer Collaborative Group (IGCCCG) good prognosis; 2 of 86 intermediate prognosis (both nonseminoma). No deaths occurred. CONCLUSION In our cohort of stage 1 testicular cancer, where national surveillance recommendations have been widely adopted, recurrences were detected at routine surveillance visits and, almost exclusively, asymptomatic with IGCCCG good-prognosis disease. This provides reassurance that active surveillance is safe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Testicular NeoplasmsSeminomaProstatic NeoplasmsMaleHumansAdolescentYoung AdultAdultMiddle AgedAgedNew ZealandNeoplasm Recurrence, LocalNeoplasm StagingRetrospective StudiesAustraliaRecurrence

Autor:innen und Institutionen

  • Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
  • Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australia.
  • ONTrac at Peter Mac, Victorian Adolescent and Young Adult Cancer Service, Melbourne, VIC, Australia.
  • Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia.

ORCID-Profile: Ciara Conduit, Jeremy Lewin, Andrew Weickhardt, James Lynam, Peter Grimison, Shomik Sengupta, Aaron R Hansen, Margaret McJannett, Martin R Stockler, Peter Gibbs, Guy Toner, Ian D Davis, Anna Kuchel

Zitieren

APA

Conduit, C., Lewin, J., Weickhardt, A., Lynam, J., Wong, S., Grimison, P., Sengupta, S., Pranavan, G., Parnis, F., Bastick, P., Campbell, D., Hansen, A. R., Leonard, M., McJannett, M., Stockler, M. R., Gibbs, P., Toner, G., Davis, I. D., Tran, B., & Kuchel, A. (2023). Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations. JCO Oncology Practice, 19(11), 973-980. https://doi.org/10.1200/op.23.00191

Vancouver

Conduit C, Lewin J, Weickhardt A, Lynam J, Wong S, Grimison P, et al. Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations. JCO Oncology Practice. 2023;19(11):973-980. doi:10.1200/op.23.00191

BibTeX
@article{Conduit2023,
  author = {Conduit, Ciara and Lewin, Jeremy and Weickhardt, Andrew and Lynam, James and Wong, Shirley and Grimison, Peter and Sengupta, Shomik and Pranavan, Ganes and Parnis, Francis and Bastick, Patricia and Campbell, David and Hansen, Aaron R and Leonard, Matt and McJannett, Margaret and Stockler, Martin R and Gibbs, Peter and Toner, Guy and Davis, Ian D and Tran, Ben and Kuchel, Anna},
  title = {Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations},
  journal = {JCO Oncology Practice},
  year = {2023},
  volume = {19},
  number = {11},
  pages = {973--980},
  doi = {10.1200/op.23.00191}
}
Kostenlos starten →